Anti-Fibronectin antibody [F14] (ab45688)
- Product nameAnti-Fibronectin antibody [F14]See all Fibronectin primary antibodies ...
- DescriptionRabbit monoclonal [F14] to Fibronectin
- Tested applicationsWB, IHC-P more details
- Species reactivityReacts with: Mouse, Rat, Human
Recombinant full length protein (Human)
- Positive controlHuman uterus.
- General notesProduced under U.S. Patent No. 5,675,063.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
- PurityTissue culture supernatant
- Clonality Monoclonal
- Clone numberF14
Our Abpromise guarantee covers the use of ab45688 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/1000 - 1/10000. Detects a band of approximately 263 kDa (predicted molecular weight: 263 kDa).|
|IHC-P||IHC-P: 1/250 - 1/500.|
- FunctionFibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape.
Anastellin binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.
- Tissue specificityPlasma FN (soluble dimeric form) is secreted by hepatocytes. Cellular FN (dimeric or cross-linked multimeric forms), made by fibroblasts, epithelial and other cell types, is deposited as fibrils in the extracellular matrix. Ugl-Y1, Ugl-Y2 and Ugl-Y3 are found in urine.
- Involvement in diseaseGlomerulopathy with fibronectin deposits 2 (GFND2) [MIM:601894]: Genetically heterogeneous autosomal dominant disorder characterized clinically by proteinuria, microscopic hematuria, and hypertension that leads to end-stage renal failure in the second to fifth decade of life. Note=The disease is caused by mutations affecting the gene represented in this entry.
- Sequence similaritiesContains 12 fibronectin type-I domains.
Contains 2 fibronectin type-II domains.
Contains 16 fibronectin type-III domains.
- Developmental stageUgl-Y1, Ugl-Y2 and Ugl-Y3 are present in the urine from 0 to 17 years of age.
It is not known whether both or only one of Thr-2064 and Thr-2065 are/is glycosylated.
Forms covalent cross-links mediated by a transglutaminase, such as F13A or TGM2, between a glutamine and the epsilon-amino group of a lysine residue, forming homopolymers and heteropolymers (e.g. fibrinogen-fibronectin, collagen-fibronectin heteropolymers).
Phosphorylation sites are present in the extracellular medium.
Proteolytic processing produces the C-terminal NC1 peptide, anastellin.
- Cellular localizationSecreted > extracellular space > extracellular matrix.
- CIG antibodyCold insoluble globulin antibodyCold-insoluble globulin antibody
- DKFZp686F10164 antibodyDKFZp686H0342 antibodyDKFZp686I1370 antibodyDKFZp686O13149 antibodyED B antibodyfibronectin 1 antibodyFINC antibodyFINC_HUMAN antibodyFN 1 antibodyFN antibodyFN1 antibodyFNZ antibodyGFND antibodyGFND2 antibodyLETS antibodyMigration stimulating factor antibodyMSF antibodyTransformation sensitive protein. antibodyUgl-Y3 antibody
Anti-Fibronectin antibody [F14] images
Anti-Fibronectin antibody [F14] (ab45688) at 1/5000 dilution + human serum
Predicted band size : 263 kDa
Observed band size : 263 kDa
Ab45688 (1:250) staining human Fibronectin in human uterus by immunohistochemistry using paraffin embedded tissue.